ArticleBiomedical engineering letters2026
A multiscale computational model of cardiac electrophysiology for drug-induced pro-arrhythmic risk stratification.
Article in Biomedical engineering letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative positions in silico simulations as essential tools for cardiac safety assessment. While single-cell simulations reveal ionic perturbations, they under-represent tissue-scale conduction, electrotonic coupling, and spatial heterogeneity that shape organ-level arrhythmogenesis. Investigate whether a multiscale classifier that combines a single-cell biomarker (qNet) with an organ-level metric (simulated QT) improves Torsades de Pointes (TdP) risk stratification over either biomarker alone. Twenty-eight CiPA drugs were simulated at 1-4×Cmax. We derived Avg. qNet from single-cell simulations (2,000 IC50-h samples × 4 concentrations) and Avg. QT from 3D tissue simulations (median parameters). Ordinal Logistic Regression (OLR) models were evaluated under split-sample (12/16) and full-set (28) analyses. Avg. qNet outperformed Avg. QT. Adding Avg. QT to Avg. qNet provided no material gain across AUC, ordinal calibration, likelihood ratios (LR±), and error rates, with only a small improvement for identifying high-risk drugs in the full-set analysis. Within this framework and dataset, ECG-derived QT is insufficient as a standalone predictor of tissue-level arrhythmogenicity; Avg. qNet is a robust primary biomarker, and the multiscale (Avg. qNet + Avg. QT) model offers at most incremental benefit. Multiscale gains will likely require ECG features that capture conduction/dispersion and larger, more diverse cohorts. Supplementary Information: The online version contains supplementary material available at 10.1007/s13534-025-00510-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.